$Galmed Pharmaceuticals Ltd. - Ordinary Shares(GLMD)$ 公司将在美国东部时间上午8点召开会议，讨论Aramchol治疗非酒精性脂肪肝(NASH)临床2b期试验52周结果。
| 发布于: | 雪球 | 转发：0 | 回复：1 | 喜欢：1 |
$Galmed Pharmaceuticals Ltd. - Ordinary Shares(GLMD)$ 公司将在美国东部时间上午8点召开会议，讨论Aramchol治疗非酒精性脂肪肝(NASH)临床2b期试验52周结果。
虽然meet,但结果并不是好于其它公司。i) significantly more patients treated with Aramchol 600mg vs. placebo achieved NASH resolution without worsening of fibrosis (16.7% vs. 5.0%; p=0.0514) and NASH resolution (19.2% vs. 7.5%; p=0.0462); and (ii) a higher proportion of patients showed at least one-point improvement in fibrosis score without worsening of NASH in Aramchol 600mg vs. placebo (29.5% vs. 17.5%; p=0.2110).